

INVITATION

Evaluating CLL treatment efficacy:

how to interpret progression-free survival, time to next treatment and MRD?

DATE November 17th, 2025

PLACE Clarion Hotel Arlanda, Sweden, room Tokyo and via stream

TIME 17.15 -19.20, followed by light dinner for those participating onsite

A warm welcome!

Program

- 17.15 **Welcome and introduction** | Prof. Per-Ola Andersson
- 17.25 **How we treat CLL patients today compared to in the past – a short walkthrough of how the guidelines have evolved**
Prof. Emerita Eva Kimby
- 17.40 **Minimal residual disease assessment in CLL – proxy for efficacy or guiding treatment?** | Ass. Prof. Carsten Niemann
- 18.10 **Redefining efficacy and safety endpoints for CLL in the era of targeted therapy** | Prof. Stefano Molica
- 18.50 **Panel discussion**
- 19.20 **Thank you and goodbye to online participants**
- 19.30 **Dinner**

Inbjudan har skickats till läkare inom hematologi med kopia till verksamhetschefer och läkemedelskommittéer.
Lilly bekostar, i enlighet med LER, förtäring för deltagare på plats, lokalkostnad och föreläsararvode inom ramen för mötet.

Register

PARTICIPATE ON SITE



To register **to participate on site**, please scan this QR code to register!

If you have any questions about the meeting, please contact Erik Bissessar, erik.bissessar@lilly.com

PARTICIPATE ONLINE



To participate **online**, please scan this QR code to register!

Speakers



Stefano Molica



Eva Kimby



Carsten Niemann



Per-Ola Andersson